Apixaban thromboprophylaxis in ambulatory patients with cancer and obesity: Insights from the AVERT trial.

MLA

Potere, Nicola, et al. “Apixaban Thromboprophylaxis in Ambulatory Patients with Cancer and Obesity: Insights from the AVERT Trial.” Thrombosis Research, vol. 226, June 2023, pp. 82–85. EBSCOhost, https://doi.org/10.1016/j.thromres.2023.04.015.

APA

Potere, N., Di Nisio, M., Porreca, E., Wang, T.-F., Tagalakis, V., Shivakumar, S., Delluc, A., Mallick, R., Wells, P. S., & Carrier, M. (2023). Apixaban thromboprophylaxis in ambulatory patients with cancer and obesity: Insights from the AVERT trial. Thrombosis Research, 226, 82–85. https://doi.org/10.1016/j.thromres.2023.04.015

Chicago

Potere, Nicola, Marcello Di Nisio, Ettore Porreca, Tzu-Fei Wang, Vicky Tagalakis, Sudeep Shivakumar, Aurélien Delluc, Ranjeeta Mallick, Phil S Wells, and Marc Carrier. 2023. “Apixaban Thromboprophylaxis in Ambulatory Patients with Cancer and Obesity: Insights from the AVERT Trial.” Thrombosis Research 226 (June): 82–85. doi:10.1016/j.thromres.2023.04.015.